

Highlights of This Issue 1971

SPECIAL FEATURES

Molecular Pathways

- 1973 | **Targeting Multiple Kinase Pathways: A Change In Paradigm**
Lucy Gossage and Tim Eisen

CCR New Strategies

- 1979 | **New Strategies in Estrogen Receptor-Positive Breast Cancer**
Stephen R.D. Johnston

Review

- 1988 | **Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis**
Srdan Verstovsek

HUMAN CANCER BIOLOGY

- 1997 | **DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma**
Kuan-Ting Kuo, Tsui-Lien Mao, Xu Chen, Yuanjian Feng, Kentaro Nakayama, Yue Wang, Ruth Glas, M. Joe Ma, Robert J. Kurman, Ie-Ming Shih, and Tian-Li Wang
- 2009 | **Decreased Selenium-Binding Protein 1 in Esophageal Adenocarcinoma Results from Posttranscriptional and Epigenetic Regulation and Affects Chemosensitivity**
Amy L. Silvers, Lin Lin, Adam J. Bass, Guoan Chen, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Thomas J. Giordano, Mark B. Orringer, David G. Beer, and Andrew C. Chang
- 2022 | **Expression Profiles and Clinical Correlations of Degradome Components in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma**
Angela Stokes, Juho Joutsa, Risto Ala-aho, Mark Pitchers, Caroline J. Pennington, Craig Martin, Don J. Premachandra, Yasunori Okada, Juha Peltonen, Reidar Grénman, Helen A. James, Dylan R. Edwards, and Veli-Matti Kähäri

2036 | **Subtype-Specific *FBXW7* Mutation and *MYCN* Copy Number Gain in Wilms' Tumor**

Richard D. Williams, Reem Al-Saadi, Tasnim Chagtai, Sergey Popov, Boo Messahel, Neil Sebire, Manfred Gessler, Jenny Wegert, Norbert Graf, Ivo Leuschner, Mike Hubank, Chris Jones, Gordan Vujanic, Kathy Pritchard-Jones, Children's Cancer and Leukaemia Group, and SIOP Wilms' Tumour Biology Group

CANCER THERAPY: PRECLINICAL

2046 | ***In vitro* and *In vivo* Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts**

Faustino Mollinedo, Janis de la Iglesia-Vicente, Consuelo Gajate, Ander Estella-Hermoso de Mendoza, Janny A. Villa-Pulgarin, Mercè de Frias, Gaël Roué, Joan Gil, Dolors Colomer, Miguel A. Campanero, and Maria J. Blanco-Prieto

2055 | **Viral Response to Chemotherapy in Endemic Burkitt Lymphoma**

Weihua Tang, Paula Harmon, Margaret L. Gulley, Charles Mwansambo, Peter N. Kazembe, Francis Martinson, Clifford Wokocho, Shannon C. Kenney, Irving Hoffman, Carlie Sigel, Susan Maygarden, Mariah Hoffman, and Carol Shores

2065 | **Reciprocal Regulation of Activating and Inhibitory Fcγ Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy**

Jonathan P. Butchar, Payal Mehta, Steven E. Justiniano, Kristan D. Guenterberg, Sri-Vidya Kondadasula, Xiaokui Mo, Mahesh Chemudupati, Thirumala-Devi Kanneganti, Amal Amer, Natarajan Muthusamy, David Jarjoura, Clay B. Marsh, William E. Carson III, John C. Byrd, and Susheela Tridandapani

- 2076 ***In vitro* and *In vivo* Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762**
James B. Mitchell, Rajani Choudhuri, Kristin Fabre, Anastasia L. Sowers, Deborah Citrin, Sonya D. Zabludoff, and John A. Cook
- 2085 **A Bispecific Eneidyne-Energized Fusion Protein Containing Ligand-Based and Antibody-Based Oligopeptides against Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Shows Potent Antitumor Activity**
Xiao-fang Guo, Xiao-fei Zhu, Yue Shang, Sheng-hua Zhang, and Yong-su Zhen
- 2095 **Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma**
Gang Niu, Xilin Sun, Qizhen Cao, Donald Courter, Albert Koong, Quynh-Thu Le, Sanjiv Sam Gambhir, and Xiaoyuan Chen
- 2131 **Gene Signatures for the Prediction of Response to Bacillus Calmette-Guérin Immunotherapy in Primary pT1 Bladder Cancers**
Yong-June Kim, Yun-Sok Ha, Seon-Kyu Kim, Hyung Yoon Yoon, Min Su Lym, Min-Ju Kim, Sung-Kwon Moon, Yung Hyun Choi, and Wun-Jae Kim
- 2138 **Bcl2 and Human Papilloma Virus 16 as Predictors of Outcome following Concurrent Chemoradiation for Advanced Oropharyngeal Cancer**
Anthony C. Nichols, Dianne M. Finkelstein, William C. Faquin, William H. Westra, Edmund A. Mroz, Peter Kneuert, Shahnaz Begum, William A. Michaud, Paul M. Busse, John R. Clark, and James W. Rocco
- 2147 **Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer**
April A.N. Rose, Andréé-Anne Grosset, Zhifeng Dong, Caterina Russo, Patricia A. MacDonald, Nicholas R. Bertos, Yves St-Pierre, Ronit Simantov, Michael Hallett, Morag Park, Louis Gaboury, and Peter M. Siegel

IMAGING, DIAGNOSIS, PROGNOSIS

- 2106 **Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma**
Ivan V. Litvinov, David A. Jones, Denis Sasseville, and Thomas S. Kupper
- 2115 **Germline *BRCA* Mutations Denote a Clinicopathologic Subset of Prostate Cancer**
David J. Gallagher, Mia M. Gaudet, Prodipto Pal, Tomas Kirchhoff, Lisa Balistreri, Kinjal Vora, Jasmine Bhatia, Zsofia Stadler, Samson W. Fine, Victor Reuter, Michael Zelefsky, Michael J. Morris, Howard I. Scher, Robert J. Klein, Larry Norton, James A. Eastham, Peter T. Scardino, Mark E. Robson, and Kenneth Offit
- 2122 ***MLL*-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1**
Przemyslaw Juszczynski, Scott J. Rodig, Jing Ouyang, Evan O'Donnell, Kunihiko Takeyama, Wojciech Mlynarski, Katarzyna Mycko, Tomasz Szczepanski, Anna Gaworczyk, Andrei Krivtsov, Joerg Faber, Amit U. Sinha, Gabriel A. Rabinovich, Scott A. Armstrong, Jeffery L. Kutok, and Margaret A. Shipp
- 2157 **Glutamine Synthetase Immunostaining Correlates with Pathologic Features of Hepatocellular Carcinoma and Better Survival after Radiofrequency Thermal Ablation**
Barbara Dal Bello, Laura Rosa, Nicoletta Campanini, Carmine Tinelli, Francesca Torello Viera, Gioacchino D'Ambrosio, Sandro Rossi, and Enrico M. Silini

CANCER THERAPY: CLINICAL

- 2167 **Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules**
Ranjana H. Advani, Herbert I. Hurwitz, Michael S. Gordon, Scot W. Ebbinghaus, David S. Mendelson, Heather A. Wakelee, Ute Hoch, Jeffrey A. Silverman, Nancy A. Havrilla, Craig J. Berman, Judith A. Fox, Roberta S. Allen, and Daniel C. Adelman

2176 **Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue**
Line L. Haugan Moi, Marianne Hauglid Flågeng, Sara Gandini, Aliana Guerrieri-Gonzaga, Bernardo Bonanni, Matteo Lazzeroni, Jennifer Gjerde, Ernst A. Lien, Andrea De Censi, and Gunnar Mellgren

2187 **Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors**
Marlies H.G. Langenberg, Petronella O. Witteveen, Jeanine M. Roodhart, Henk M.W. Verheul, Marja Mergui-Roelvink, Jana van der Sar, Erich Brendel, Nicole Laferriere, Jan H.M. Schellens, and Emile E. Voest

2198 **Outcome of Photodynamic Therapy Using NPe6 for Bronchogenic Carcinomas in Central Airways >1.0 cm in Diameter**
Jitsuo Usuda, Shuji Ichinose, Taichirou Ishizumi, Hiroki Hayashi, Keishi Ohtani, Sachio Maehara, Shoutarou Ono, Hidetoshi Honda, Naohiro Kajiwara, Osamu Uchida, Hidemitsu Tsutsui, Tatsuo Ohira, Harubumi Kato, and Norihiko Ikeda

2205 **Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer**
J. Randolph Hecht, Edith Mitchell, Marcus A. Neubauer, Howard A. Burris III, Paul Swanson, Timothy Lopez, Glenn Buchanan, Maureen Reiner, Jennifer Gansert, and Jordan Berlin

SUSCEPTIBILITY AND PREVENTION


2214 **Lynch Syndrome–Associated Breast Cancers: Clinicopathologic Characteristics of a Case Series from the Colon Cancer Family Registry**
Michael D. Walsh, Daniel D. Buchanan, Margaret C. Cummings, Sally-Ann Pearson, Sven T. Arnold, Mark Clendenning, Rhiannon Walters, Diane M. McKeone, Amanda B. Spurdle, John L. Hopper, Mark A. Jenkins, Kerry D. Phillips, Graeme K. Suthers, Jill George, Jack Goldblatt, Amanda Muir, Kathy Tucker, Elise Pelzer, Michael R. Gattas, Sonja Woodall, Susan Parry, Finlay A. Macrae, Robert W. Haile, John A. Baron, John D. Potter, Loic Le Marchand, Bharati Bapat, Stephen N. Thibodeau, Noralane M. Lindor, Michael A. McGuckin, and Joanne P. Young

LETTER TO THE EDITOR

2225 **Is Curcumin for Monoclonal Gammopathy of Undetermined Significance without Risk? – Letter**
Alphons J.M. Vermorken, Jingjing Zhu, and Willem J.M. Van de Ven

ABOUT THE COVER

The *in vivo* delivery and distribution of antibodies affect immunoinaging and immunotherapy outcomes. The representative immunofluorescence image of UM-SCC1 tumor section shows a patchy distribution of cetuximab, an antibody against EGFR. At 24 hours after tail vein injection, the antibody only diffused around the perivascular regions within the diameter of several cells. In this image, cetuximab is displayed in green with FITC conjugation and tumor vasculature in red as stained with antimurine CD31 antibody. The blue color is from DAPI for nuclei visualization. For details, see the article by Niu and colleagues on page 2095 of this issue.



Clinical Cancer Research

16 (7)

Clin Cancer Res 2010;16:1971-2225.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.